(MedPage Today) — SAN JUAN, PUERTO RICO — As many as 70% of patients with advanced/metastatic HER2-expressing endometrial cancer (EC) responded to an investigational antibody-drug conjugate (ADC), according to phase II data.
Response to trastuzumab…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
